5th Nov 2012 15:14
For immediate release | 5 November 2012 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR dealing: Share Incentive Plan
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that following completion of three years of continued employment since the award of Matching Shares under the Share Incentive Plan on 5 November 2009, the risk of forfeiture attached to these shares has now been removed, resulting in an increase in the beneficial holding of each Director/PDMR as follows:
Name | Matching Shares now transferred to beneficial ownership | Total subsequent beneficial holding | Percentage of share capital | |
Executive Directors: | Jonathan Milner | 800 | 27,930,632 | 14.08% |
Jim Warwick | 800 | 2,940,432 | 1.48% | |
Jeff Iliffe | 800 | 22,632 | 0.01% | |
PDMR: | Mark Bushfield | 65 | 4,105 | 0.002% |
Jane Cooke | 800 | 9,021 | 0.005% | |
Philippe Cotrel | 70 | 7,722 | 0.004% | |
Ed Ralph | 800 | 363,352 | 0.183% |
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Andy Crossley - Corporate Broking
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 600 staff across its eight operating companies.
Abcam now has an online catalogue of over 98,900 products sourced from over 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.
Related Shares:
ABC.L